The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study (TREAT)
NCT ID: NCT03113006
Last Updated: 2019-08-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
53 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-05-01
Study Completion Date
2019-08-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background Diabetic eye disease is the most frequent complication among the 320,000 Danes with diabetes. The formation of new vessels (PDR) in the inner part of the eye (retina) is a feared complication and a leading cause of blindness, since these vessels are fragile and often cause bleeding within the eye. Peripheral retinal laser treatment (PRP) halves the risk of blindness, but often comes with a high prize. The peripheral part of the retina is responsible for the visual field and the night vision, and PRP limits these abilities (i.e. loss of driving license).
The technique of PRP has principally been the same for the past 40 years with standard treatment given for all patients. With this one size fits all approach, a substantial number of patients will either be treated too much or too little. Too little treatment is inefficient, and disease progression may occur. Excessive treatment may cause side effects like loss of visual fields and decreased night vision. Therefore, it is important to test if treatment can be applied on an individual basis to give high efficacy treatment with minimal side effects.
IMPETUS 2018 - TREAT is the second of two studies aimed at making an individual design for retinal laser treatment. In IMPETUS 2018 - DETECT the investigators demonstrated that non-invasive examinations of the oxygen level and measurements of the retinal vascular tree provide important information of individual treatment response. For instance, if standard PRP led to three per cent higher retinal oxygen saturation, there was a 4-fold risk of disease progression despite treatment. Hence, such a patient would benefit from more treatment to avoid blindness. With these observations at hand, the investigators want to compare a less invasive treatment (individualized laser treatment) against the standard PRP.
Another essential aspect in the treatment of PDR is to be able to give the right diagnosis and to evaluate the efficacy of laser treatment. So far, this has been performed by fluorescein angiography. However, this examination are highly person-dependent and unpleasant to patients, and a more objective approach is needed. Optical coherent tomography angiography (OCT-A) is a quick, noninvasive scanning of the retina which is ideal to visualize moving objects like blood within the retinal vessels. The method has been successfully implemented in a number of retinal diseases, but it has never been validated in PDR.
Standard PRP is often performed in 3-4 sessions. However, it may be painful, and patients sometimes choose not to complete all sessions after the initial treatment has been given. There is insufficient knowledge of the patient-barriers to treatment, and it is important to address these in an individualized treatment design.
Aim In this 6-month 1:1 randomized, prospective study the investigators want to investigate 1) whether individualized retinal laser treatment compared with standard PRP has the same efficacy but less side effects, 2) whether OCT-A can be used as an objective marker for disease activity, and 3) to obtain a better understanding of patient-reported barriers to standard laser treatment PRP and whether these can be addressed with personalized retinal laser treatment.
Setup Fifty eight consecutively recruited patients (1 May 2017 - 30 April 2018) with newly diagnosed PDR referred to the Department of Ophthalmology, OUH, and randomly assigned to standard PRP (n=29) or individualized laser treatment (n=29).
Intervention Standard laser treatment is performed in all four quadrants of the retina. Individualized laser treatment is only performed in the part(s) of the retina with proliferation(s).
Both treatments are carried out at baseline (BL), and additional treatment is given at month three (M3) and/or (M6), if necessary.
Investigations Retinal digital images, fluorescein angiography, OCT-A (BL, M3, M6). Test of visual fields, dark adaptation and quality of life (BL, M6). Semi-structured interview will be performed with five patients who have received PRP in one eye and individualized laser treatment in the other eye. This will address treatment experience, potential barriers to treatment, etc.
What to measure:
Differences in need for retreatment, night blindness, visual fields, visual acuity, bleeding in the eye, surgery, and quality of life between the groups.
The technique of PRP has principally been the same for the past 40 years with standard treatment given for all patients. With this one size fits all approach, a substantial number of patients will either be treated too much or too little. Too little treatment is inefficient, and disease progression may occur. Excessive treatment may cause side effects like loss of visual fields and decreased night vision. Therefore, it is important to test if treatment can be applied on an individual basis to give high efficacy treatment with minimal side effects.
IMPETUS 2018 - TREAT is the second of two studies aimed at making an individual design for retinal laser treatment. In IMPETUS 2018 - DETECT the investigators demonstrated that non-invasive examinations of the oxygen level and measurements of the retinal vascular tree provide important information of individual treatment response. For instance, if standard PRP led to three per cent higher retinal oxygen saturation, there was a 4-fold risk of disease progression despite treatment. Hence, such a patient would benefit from more treatment to avoid blindness. With these observations at hand, the investigators want to compare a less invasive treatment (individualized laser treatment) against the standard PRP.
Another essential aspect in the treatment of PDR is to be able to give the right diagnosis and to evaluate the efficacy of laser treatment. So far, this has been performed by fluorescein angiography. However, this examination are highly person-dependent and unpleasant to patients, and a more objective approach is needed. Optical coherent tomography angiography (OCT-A) is a quick, noninvasive scanning of the retina which is ideal to visualize moving objects like blood within the retinal vessels. The method has been successfully implemented in a number of retinal diseases, but it has never been validated in PDR.
Standard PRP is often performed in 3-4 sessions. However, it may be painful, and patients sometimes choose not to complete all sessions after the initial treatment has been given. There is insufficient knowledge of the patient-barriers to treatment, and it is important to address these in an individualized treatment design.
Aim In this 6-month 1:1 randomized, prospective study the investigators want to investigate 1) whether individualized retinal laser treatment compared with standard PRP has the same efficacy but less side effects, 2) whether OCT-A can be used as an objective marker for disease activity, and 3) to obtain a better understanding of patient-reported barriers to standard laser treatment PRP and whether these can be addressed with personalized retinal laser treatment.
Setup Fifty eight consecutively recruited patients (1 May 2017 - 30 April 2018) with newly diagnosed PDR referred to the Department of Ophthalmology, OUH, and randomly assigned to standard PRP (n=29) or individualized laser treatment (n=29).
Intervention Standard laser treatment is performed in all four quadrants of the retina. Individualized laser treatment is only performed in the part(s) of the retina with proliferation(s).
Both treatments are carried out at baseline (BL), and additional treatment is given at month three (M3) and/or (M6), if necessary.
Investigations Retinal digital images, fluorescein angiography, OCT-A (BL, M3, M6). Test of visual fields, dark adaptation and quality of life (BL, M6). Semi-structured interview will be performed with five patients who have received PRP in one eye and individualized laser treatment in the other eye. This will address treatment experience, potential barriers to treatment, etc.
What to measure:
Differences in need for retreatment, night blindness, visual fields, visual acuity, bleeding in the eye, surgery, and quality of life between the groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Low-Fluence PRP for PDR
NCT01737957
Proliferative Diabetic Retinopathy
TERMINATED
NA
Severe Proliferative Diabetic Retinopathy
NCT01115257
Diabetic Retinopathy
COMPLETED
NA
Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy
NCT06549023
Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Diabetic Retinopathy Visually Threatening
+3 more
RECRUITING
NA
Prophylactic PRP in Moderate NPDR
NCT05543564
Eye Diseases
Diabetes
Diabetic Retinopathy
COMPLETED
Loss to Follow-up in PDR Patients
NCT04018326
Diabetic Retinopathy
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction Diabetes mellitus is an epidemic disorder, which in Denmark alone is affecting 320,000 patients. Diabetic retinopathy (DR) is the most frequent long term complication to diabetes mellitus (1) and a feared cause of severe vision loss and blindness (2).
Proliferative diabetic retinopathy (PDR) is the major cause of severe visual loss. Lack of oxygen to the retina (retinal ischemia) results in up-regulation of, in particular, the growth factor vascular endothelial growth factor (VEGF) (3) followed by compensatory retinal proliferations. The neovasculature is fragile and often leads to vitreous hemorrhages or retinal detachment which makes the patient at high risk of irreversible vision loss (4).
In 1976 it was shown that patients with severe PDR can halve the risk of severe vision loss by peripheral retinal laser treatment (photocoagulation panretinal, PRP) (5). This treatment reduces the retina's oxygen demand, which makes the VEGF concentration decrease and the proliferations shrink (5).
PRP has largely been the same for the last 40 years. The standard treatment is basically the same for all patients (4 + 6), which leads to some patients being either over or under treated. If treatment is inadequate, patients are in risk of disease progression and thus difficult vision loss (7). On the other hand, the treatment may cause side effects in the form of loss of visual field (8-9), night vision loss (10) and accumulation of fluid in the eye's macula (diabetic macular edema) (11).
This study is a continuum of the clinical project IMPETUS 2018 - DETECT, which aimed to identify the factors that were important for a successful PRP treatment of PDR. In the study the investigators prospectively followed 65 patients with newly diagnosed PDR. All patients received baseline navigated PRP, as in Scandinavia only offered at Odense University Hospital (OUH). Navigated panretinal laser with a Navilas® laser ensures optimized treatment (12), shorter treatment (13) and increased patient comfort (12-14). Treatment effect was investigated at month three and six, and if necessary, treatment was supplied. All the patients venous retinal oxygen saturation was measured to study whether this had any therapeutic value.
The investigators observed that the retinal oxygen saturation was a strong predictor of treatment response. Compared to patients whose disease was slowed down after treatment, patients with progression three months after PRP had an increase in the venous retinal oxygen saturation (+ 4.1% vs. -1.8%, p = 0.02). Patients with an increase of at least 3.0% in venous retinal oxygen saturation had 4.0 times greater risk of disease progression than patients who were below this threshold (15). This observation is in line with another Danish study, which demonstrated that worsening of DR causes increased venous retinal oxygen saturation (16). By measuring if this increase in venous retinal oxygen saturation has slowed down, one can assess whether PRP treatment is sufficient.
PDR is traditionally perceived as an ischemic disease, which initially affects the entire retina. In our above mentioned study the investigators were able to confirm the results regarding the venous retinal oxygen saturation in the affected segment of the retina, in 24 of the patients in the study, who had only one peripheral proliferation. In these patients the oxygen saturation was increased with disease progression (+ 3.9% vs. -1.5%, p = 0.04). This indicates that the focal hypoxia are more important than previously thought, and thus the local treatment of the diseased area may be a treatment option that reduces the processing volume, thereby minimizing potential side effects.
Retinal proliferations are fragile and often leak contrast fluid. When initiating the study, the investigators expected the leakage of fluorescein over time would be the optimal method to assess disease activity, but had to realize that this method was difficult to objectify (17). As an alternative to this objective evaluation, it is possible to observe the structural conditions at the interface between the retina and vitreous body (18), but technological limitations have so far prevented the possibility of repeated evaluations of the same lesion over time. Optical coherency tomography (OCT)-angiography is, however, a new method that can visualize retinal structures and potential development of these in detail (19).
Purpose In a six-month randomized, prospective study of patients with newly diagnosed PDR the investigators want to investigate 1) whether individualized PRP compared with standard PRP has the same efficacy but less side effects and 2) whether OCT angiography can be used as a marker for disease activity in PDR.
Hypothesis The investigators expect that 1) individualized PDR provides the same effect but fewer side effects and better quality of life than traditional PDR, and 2) OCT angiography has better sensitivity and specificity than wide field fluorescein angiography (FA) for the evaluation of disease activity by PDR.
Methods
Setup:
* Six-months 1: 1 randomized, prospective study.
* 58 consecutively recruited patients with newly diagnosed PDR at the Department of Ophthalmology, University Hospital, included in the period 1 March 2017 to 28 February 2018.
* Patients will be randomized to either 1) standard PRP with Navilas® (n = 29) or individualized PRP with Navilas® (n = 29). To ensure the same degree of ischemic disease, the two groups are balanced in relation to the number of retinal quadrants with proliferations.
Intervention:
* Standard PRP: localized to all four retinal quadrants.
* Individualized PRP: localized to the affected quadrants.
* Both treatments are carried out at baseline (BL) and supplemented if there is increasing disease activity at month three (M3) and / or month six (M6).
* Indications for additional treatment:
* Progression of PDR in the form of subjective growing lesion (assessed by ophthalmoscopy and wide field fundus photo) or increasing leakage wide field FA (M3 or M6).
* Progression of PDR in terms of objectively progressive lesion (≥10% from BL) measured by spectral domain (SD) OCT or OCT angiography (M3 or M6).
* Increase in venous retinal oxygen saturation of at least + 3,0% between BL and M3.
Investigations:
* Demographics: age, sex, type of diabetes, diabetes duration, smoking, drugs (BL).
* Objectively: Blood pressure, height, weight (BL).
* Blood samples: HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, P creatinine, eGFR (BL, M3, M6).
* Visual acuity (Best Corrected Early Treatment Diabetic Retinopathy Study standard) (BL, M3, M6).
* Intraocular pressure (BL, M3, M6).
* SD-OCT (Topcon 3D OCT 2000): macula and area(s) with PDR (BL, M3, M6).
* OCT angiography (Topcon DRI OCT Triton): region(s) with PDR (BL, M3, M6).
* Wide field fundus photo and FA (Optos) (BL, M3, M6).
* Retinal oximetry (Oxymap T1) (BL, M3, M6).
* Dark-adaptation (Goldmann-weeker adaptometer) (BL, M6).
* Perimetry (Humphrey 30-2) (BL, M6).
* Selected components of quality of life questionnaire (Danish translation of Visual Function Questionnaire-25) (BL, M6).
Endpoints
Primary:
* Need for retreatment between the groups (M3 and M6).
* Loss of visual fields between the groups (from BL to M6).
* Change in dark adaptation between the groups (from BL to M6).
* Sensitivity and specificity of OCT angiography as an expression of disease activity in PDR (BL, M3 and M6).
Secondary:
* Change in visual acuity between the groups (from BL to M6).
* Difference in proportion with the development of vitreous haemorrhage between the groups (from BL to M6).
* Need for surgical removal of the vitreous between the groups (from BL to M6)
* Change in quality of life between the groups (from BL to M6).
Proliferative diabetic retinopathy (PDR) is the major cause of severe visual loss. Lack of oxygen to the retina (retinal ischemia) results in up-regulation of, in particular, the growth factor vascular endothelial growth factor (VEGF) (3) followed by compensatory retinal proliferations. The neovasculature is fragile and often leads to vitreous hemorrhages or retinal detachment which makes the patient at high risk of irreversible vision loss (4).
In 1976 it was shown that patients with severe PDR can halve the risk of severe vision loss by peripheral retinal laser treatment (photocoagulation panretinal, PRP) (5). This treatment reduces the retina's oxygen demand, which makes the VEGF concentration decrease and the proliferations shrink (5).
PRP has largely been the same for the last 40 years. The standard treatment is basically the same for all patients (4 + 6), which leads to some patients being either over or under treated. If treatment is inadequate, patients are in risk of disease progression and thus difficult vision loss (7). On the other hand, the treatment may cause side effects in the form of loss of visual field (8-9), night vision loss (10) and accumulation of fluid in the eye's macula (diabetic macular edema) (11).
This study is a continuum of the clinical project IMPETUS 2018 - DETECT, which aimed to identify the factors that were important for a successful PRP treatment of PDR. In the study the investigators prospectively followed 65 patients with newly diagnosed PDR. All patients received baseline navigated PRP, as in Scandinavia only offered at Odense University Hospital (OUH). Navigated panretinal laser with a Navilas® laser ensures optimized treatment (12), shorter treatment (13) and increased patient comfort (12-14). Treatment effect was investigated at month three and six, and if necessary, treatment was supplied. All the patients venous retinal oxygen saturation was measured to study whether this had any therapeutic value.
The investigators observed that the retinal oxygen saturation was a strong predictor of treatment response. Compared to patients whose disease was slowed down after treatment, patients with progression three months after PRP had an increase in the venous retinal oxygen saturation (+ 4.1% vs. -1.8%, p = 0.02). Patients with an increase of at least 3.0% in venous retinal oxygen saturation had 4.0 times greater risk of disease progression than patients who were below this threshold (15). This observation is in line with another Danish study, which demonstrated that worsening of DR causes increased venous retinal oxygen saturation (16). By measuring if this increase in venous retinal oxygen saturation has slowed down, one can assess whether PRP treatment is sufficient.
PDR is traditionally perceived as an ischemic disease, which initially affects the entire retina. In our above mentioned study the investigators were able to confirm the results regarding the venous retinal oxygen saturation in the affected segment of the retina, in 24 of the patients in the study, who had only one peripheral proliferation. In these patients the oxygen saturation was increased with disease progression (+ 3.9% vs. -1.5%, p = 0.04). This indicates that the focal hypoxia are more important than previously thought, and thus the local treatment of the diseased area may be a treatment option that reduces the processing volume, thereby minimizing potential side effects.
Retinal proliferations are fragile and often leak contrast fluid. When initiating the study, the investigators expected the leakage of fluorescein over time would be the optimal method to assess disease activity, but had to realize that this method was difficult to objectify (17). As an alternative to this objective evaluation, it is possible to observe the structural conditions at the interface between the retina and vitreous body (18), but technological limitations have so far prevented the possibility of repeated evaluations of the same lesion over time. Optical coherency tomography (OCT)-angiography is, however, a new method that can visualize retinal structures and potential development of these in detail (19).
Purpose In a six-month randomized, prospective study of patients with newly diagnosed PDR the investigators want to investigate 1) whether individualized PRP compared with standard PRP has the same efficacy but less side effects and 2) whether OCT angiography can be used as a marker for disease activity in PDR.
Hypothesis The investigators expect that 1) individualized PDR provides the same effect but fewer side effects and better quality of life than traditional PDR, and 2) OCT angiography has better sensitivity and specificity than wide field fluorescein angiography (FA) for the evaluation of disease activity by PDR.
Methods
Setup:
* Six-months 1: 1 randomized, prospective study.
* 58 consecutively recruited patients with newly diagnosed PDR at the Department of Ophthalmology, University Hospital, included in the period 1 March 2017 to 28 February 2018.
* Patients will be randomized to either 1) standard PRP with Navilas® (n = 29) or individualized PRP with Navilas® (n = 29). To ensure the same degree of ischemic disease, the two groups are balanced in relation to the number of retinal quadrants with proliferations.
Intervention:
* Standard PRP: localized to all four retinal quadrants.
* Individualized PRP: localized to the affected quadrants.
* Both treatments are carried out at baseline (BL) and supplemented if there is increasing disease activity at month three (M3) and / or month six (M6).
* Indications for additional treatment:
* Progression of PDR in the form of subjective growing lesion (assessed by ophthalmoscopy and wide field fundus photo) or increasing leakage wide field FA (M3 or M6).
* Progression of PDR in terms of objectively progressive lesion (≥10% from BL) measured by spectral domain (SD) OCT or OCT angiography (M3 or M6).
* Increase in venous retinal oxygen saturation of at least + 3,0% between BL and M3.
Investigations:
* Demographics: age, sex, type of diabetes, diabetes duration, smoking, drugs (BL).
* Objectively: Blood pressure, height, weight (BL).
* Blood samples: HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, P creatinine, eGFR (BL, M3, M6).
* Visual acuity (Best Corrected Early Treatment Diabetic Retinopathy Study standard) (BL, M3, M6).
* Intraocular pressure (BL, M3, M6).
* SD-OCT (Topcon 3D OCT 2000): macula and area(s) with PDR (BL, M3, M6).
* OCT angiography (Topcon DRI OCT Triton): region(s) with PDR (BL, M3, M6).
* Wide field fundus photo and FA (Optos) (BL, M3, M6).
* Retinal oximetry (Oxymap T1) (BL, M3, M6).
* Dark-adaptation (Goldmann-weeker adaptometer) (BL, M6).
* Perimetry (Humphrey 30-2) (BL, M6).
* Selected components of quality of life questionnaire (Danish translation of Visual Function Questionnaire-25) (BL, M6).
Endpoints
Primary:
* Need for retreatment between the groups (M3 and M6).
* Loss of visual fields between the groups (from BL to M6).
* Change in dark adaptation between the groups (from BL to M6).
* Sensitivity and specificity of OCT angiography as an expression of disease activity in PDR (BL, M3 and M6).
Secondary:
* Change in visual acuity between the groups (from BL to M6).
* Difference in proportion with the development of vitreous haemorrhage between the groups (from BL to M6).
* Need for surgical removal of the vitreous between the groups (from BL to M6)
* Change in quality of life between the groups (from BL to M6).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Proliferative Diabetic Retinopathy
PDR
Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Panretinal Photocoagulation
Localized to all four retinal quadrants.
Group Type
ACTIVE_COMPARATOR
Panretinal Photocoagulation
Intervention Type
PROCEDURE
Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
Individ. Panretinal Photocoagulation
Localized to only the affected quadrants.
Group Type
EXPERIMENTAL
Panretinal Photocoagulation
Intervention Type
PROCEDURE
Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Panretinal Photocoagulation
Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
PRP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diabetes mellitus.
* Newly diagnosed, untreated PDR in one eye (the possibility of inclusion of both eyes by bilateral PDR).
* Newly diagnosed, untreated PDR in one eye (the possibility of inclusion of both eyes by bilateral PDR).
Exclusion Criteria
* Diabetic macular edema in the affected eye.
* Age \<18 years.
* Pregnancy.
* Ambiguities in refracting media on topical eye.
* Age \<18 years.
* Pregnancy.
* Ambiguities in refracting media on topical eye.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern Denmark
OTHER
Sponsor Role
collaborator
Velux Fonden
OTHER
Sponsor Role
collaborator
Odense University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anna Stage Vergmann
Ph. D. student
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna S Vergmann, M.D.
Role: PRINCIPAL_INVESTIGATOR
Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Department of Ophthalmology, Odense University Hospital
Odense, The Region of Southern Denmarj, Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Grauslund J, Green A, Sjolie AK. Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia. 2009 Sep;52(9):1829-35. doi: 10.1007/s00125-009-1450-4. Epub 2009 Jul 12.
Reference Type
BACKGROUND
Grauslund J, Green A, Sjolie AK. Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients. Ophthalmology. 2009 Nov;116(11):2170-4. doi: 10.1016/j.ophtha.2009.04.043. Epub 2009 Sep 10.
Reference Type
BACKGROUND
Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006 Jul-Aug;51(4):364-80. doi: 10.1016/j.survophthal.2006.04.005.
Reference Type
BACKGROUND
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981 Jul;88(7):583-600.
Reference Type
BACKGROUND
Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976 Apr;81(4):383-96. doi: 10.1016/0002-9394(76)90292-0.
Reference Type
BACKGROUND
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):766-85.
Reference Type
BACKGROUND
Bandello F, Brancato R, Menchini U, Virgili G, Lanzetta P, Ferrari E, Incorvaia C. Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy. Semin Ophthalmol. 2001 Mar;16(1):12-8. doi: 10.1076/soph.16.1.12.4223.
Reference Type
BACKGROUND
Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007 Sep;27(7):816-24. doi: 10.1097/IAE.0b013e318042d32c.
Reference Type
BACKGROUND
Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mild-scatter coagulation. Int Ophthalmol. 1998;22(5):313-9. doi: 10.1023/a:1006367029134.
Reference Type
BACKGROUND
Pender PM, Benson WE, Compton H, Cox GB. The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology. 1981 Jul;88(7):635-8. doi: 10.1016/s0161-6420(81)34977-x.
Reference Type
BACKGROUND
Ferris FL 3rd, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology. 1987 Jul;94(7):754-60. doi: 10.1016/s0161-6420(87)33526-2.
Reference Type
BACKGROUND
Chhablani J, Mathai A, Rani P, Gupta V, Arevalo JF, Kozak I. Comparison of conventional pattern and novel navigated panretinal photocoagulation in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014 May 1;55(6):3432-8. doi: 10.1167/iovs.14-13936.
Reference Type
BACKGROUND
Chhablani J, Sambhana S, Mathai A, Gupta V, Arevalo JF, Kozak I. Clinical efficacy of navigated panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol. 2015 May;159(5):884-9. doi: 10.1016/j.ajo.2015.02.006. Epub 2015 Feb 19.
Reference Type
BACKGROUND
Inan UU, Polat O, Inan S, Yigit S, Baysal Z. Comparison of pain scores between patients undergoing panretinal photocoagulation using navigated or pattern scan laser systems. Arq Bras Oftalmol. 2016 Feb;79(1):15-8. doi: 10.5935/0004-2749.20160006.
Reference Type
BACKGROUND
Torp TL, Kawasaki R, Wong TY, Peto T, Grauslund J. Improvement in retinal venous oxygen saturation after panretinal photocoagulation is predictive of progression of proliferative diabetic retinopathy. ARVO, 2016;6356-C0143.
Reference Type
BACKGROUND
Jorgensen CM, Hardarson SH, Bek T. The oxygen saturation in retinal vessels from diabetic patients depends on the severity and type of vision-threatening retinopathy. Acta Ophthalmol. 2014 Feb;92(1):34-9. doi: 10.1111/aos.12283. Epub 2013 Dec 16.
Reference Type
BACKGROUND
Torp TL, Frydkjær-Olsen U, Hansen RS, Peto T, Grauslund J. Intra- and intergrader reliability of semiautomatic measurements of fundus fluorescein angiography leakage in proliferative diabetic retinopathy. European Journal of Ophthalmology, 2015;25(3):e7-e30.
Reference Type
BACKGROUND
Lee CS, Lee AY, Sim DA, Keane PA, Mehta H, Zarranz-Ventura J, Fruttiger M, Egan CA, Tufail A. Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiography. Am J Ophthalmol. 2015 Jan;159(1):101-10.e1. doi: 10.1016/j.ajo.2014.09.041. Epub 2014 Oct 25.
Reference Type
BACKGROUND
de Carlo TE, Bonini Filho MA, Baumal CR, Reichel E, Rogers A, Witkin AJ, Duker JS, Waheed NK. Evaluation of Preretinal Neovascularization in Proliferative Diabetic Retinopathy Using Optical Coherence Tomography Angiography. Ophthalmic Surg Lasers Imaging Retina. 2016 Feb;47(2):115-9. doi: 10.3928/23258160-20160126-03.
Reference Type
BACKGROUND
Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
Reference Type
BACKGROUND
Vergmann AS, Sorensen KT, Torp TL, Kawasaki R, Wong T, Peto T, Grauslund J. Optical coherence tomography angiography measured area of retinal neovascularization is predictive of treatment response and progression of disease in patients with proliferative diabetic retinopathy. Int J Retina Vitreous. 2020 Nov 4;6(1):49. doi: 10.1186/s40942-020-00249-6.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-20160168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser
NCT01304225
UNKNOWN
PHASE3
Long Term Follow-Up of Diabetic Retinopathy
NCT00001395
COMPLETED
Diabetes PRP and OCT
NCT01928550
COMPLETED
Macular Vessels Density Before and After PRP in Patients With Proliferative Diabetic Retinopathy
NCT04976361
COMPLETED
NA
Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters
NCT01023698
TERMINATED
NA
Investigating the Structural and Functional Changes to the Retina Following PRP in Diabetic Retinopathy Patients
NCT02621580
COMPLETED
NA
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
NCT04103671
RECRUITING
NA
Effect of Argon Laser Panretinal Photocoagulation on Corneal Endothelial Cell Density .
NCT07157553
NOT_YET_RECRUITING
Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy
NCT00355680
COMPLETED
PHASE3
Pharmacological Intervention in Diabetic Retinopathy
NCT00619034
COMPLETED
NA
Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy
NCT02309502
WITHDRAWN
NA
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
NCT04674254
COMPLETED
PHASE4
Anti-VEGF Treatment for Prevention of PDR/DME
NCT02634333
COMPLETED
PHASE3
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.
NCT01766362
COMPLETED
PHASE3
Propranolol for Diabetic Retinopathy
NCT01535495
COMPLETED
PHASE1
Biomarkers of Diabetic Retinopathy Progression
NCT01607190
COMPLETED
Prophylactic Laser Treatment of Drusen Maculopathy
NCT00348543
COMPLETED
NA
The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes
NCT03150654
COMPLETED
NA
Topical Application of Latanoprost in Diabetic Retinopathy
NCT01225653
COMPLETED
PHASE4
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
NCT03633266
UNKNOWN
NA
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases
NCT07341919
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Panretinal Photocoagulation During Vitrectomy for Diabetic Vitreous Hemorrhage
NCT05318742
UNKNOWN
NA
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
NCT02554747
COMPLETED
NA
Evaluation of the Effects of Selective Photocoagulation for the Treatment of Diabetic Macular Edema
NCT01355692
COMPLETED
PHASE2/PHASE3
Comparison of Two Laser Therapy Methods for PDR
NCT01232179
UNKNOWN
PHASE2